Phoenix winnonlin software version 7

Female Balb/c mice (n = 3, 6 weeks, 20 g) received an intraperitoneal injection of either hIL15 (1 µg) or equimolar hIL15-ABD (1.5 µg) in 300 µL of PBS. For mice injected with hIL15, in time intervals of 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, whereas for mice treated with hIL15-ABD, in time intervals of 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 8 h, 24 h, 36 h, and 52 h, blood samples were withdrawn from the tail and placed on ice. Serum samples were obtained by centrifuging clotted blood at 800 g for 10 min at 4 °C. Serum concentrations of hIL15 and hIL15-ABD were determined by ELISA specific for human hIL15 (DY247-05, R&DSystem, Minneapolis, MN, USA). Pharmacokinetic parameters were determined using the Phoenix^® WinNonlin software version 7.0 (Certara USA Inc., Princeton, NJ, USA). Noncompartmental analysis (extravascular input) was used with the log/linear trapezoidal rule. Parameters, including terminal half-life (T_1/2λz), Tmax, Cmax and area under the curve (AUC) were determined. Pharmacokinetic parameters associated with the terminal phase were calculated using the last four measured time points to estimate the terminal half-life.

Plasma concentrations of FTD and TPI were monitored at five time points on day 8, including before, 45 min, 90 min, 180 min, and 360 min after FTD/TPI administration in the morning. The area under curve (AUC) of the plasma concentration from 0 to 10 h of FTD and TPI [13 (link)] were analyzed by a noncompartmental model from the plasma concentration of each blood sampling time (Phoenix WinNonlin software Version 7.0, Certara USA, Inc., Princeton, NJ, USA).